(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 92.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Syndax Pharmaceuticals's revenue in 2025 is $78,180,000.On average, 4 Wall Street analysts forecast SNDX's revenue for 2025 to be $14,846,980,625, with the lowest SNDX revenue forecast at $11,775,592,535, and the highest SNDX revenue forecast at $16,727,888,182. On average, 4 Wall Street analysts forecast SNDX's revenue for 2026 to be $31,159,665,032, with the lowest SNDX revenue forecast at $18,684,169,868, and the highest SNDX revenue forecast at $40,872,590,682.
In 2027, SNDX is forecast to generate $47,793,658,584 in revenue, with the lowest revenue forecast at $39,228,142,536 and the highest revenue forecast at $62,466,632,648.